Genmab(US:GMAB)2026-02-17 18:02Financial Data and Key Metrics Changes - Total revenue increased by 19% to $3.7 billion in 2025, driven by strong execution across the royalty portfolio and commercialized medicines [24][26] - Operating profit expanded to $1.26 billion, reflecting strong execution and increasing operating leverage as the business scales [25][29] - Sales of proprietary medicines totaled $632 million, up 54% year over year, accounting for approximately 28% of total revenue growth [16][24] Business Line Data and Key Metrics Changes - EPKINLY achieved $468 million in sales for the year, representing a 67% year-over-year increase, driven by its dual indication in diffuse large B-cell lymphoma and follicular lymphoma [17][19] - TIVDAK generated $164 million in sales, representing a 26% year-over-year increase, highlighting its continued market leadership in recurrent or metastatic cervical cancer [20][21] Market Data and Key Metrics Changes - EPKINLY closed 2025 with regulatory approvals in more than 65 countries, nearly all featuring the dual indication [17] - TIVDAK's launch in Germany showed strong, consistent uptake and positive physician feedback, indicating a successful entry into new markets [21][22] Company Strategy and Development Direction - The company aims to accelerate the development of its late-stage pipeline and maximize the potential of its commercialized medicines, with a focus on sustainable growth into the 2030s [5][6] - The acquisition of Merus is expected to enhance the late-stage portfolio with petosemtamab, providing multiple value-creating catalysts in 2026 and beyond [8][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in executing key data readouts in 2026 and subsequent high-impact launches in 2027, emphasizing a disciplined approach to capital allocation and investment prioritization [30][29] - The company anticipates continued momentum in EPKINLY and its royalty portfolio, with a revenue growth guidance of 14% for 2026 [26][29] Other Important Information - The company has five combined breakthrough therapy designations for its late-stage programs, indicating significant long-term growth potential [9] - Management highlighted the importance of maximizing first-mover advantage in second-line follicular lymphoma in the U.S. and anticipated approvals in Europe and Japan [19][20] Q&A Session Summary Question: Next steps for EPKINLY following EPCORE DLBCL-1 study results - Management confirmed that the 05 study showed positive progression-free survival but missed overall survival, with ongoing discussions with regulatory agencies regarding the data set [33][34] Question: Update on outpatient data for EPKINLY - Management indicated that the outpatient study is crucial for modifying the label and facilitating administration in the community [41][44] Question: Expectations for Rina-S pivotal phase II readout - Management stated that the study is designed to support accelerated approval based on overall response rate and duration of response [50][51] Question: Expectations for EPCORE DLBCL-4 trial outcomes - Management expressed optimism that the trial will lead to registration in second-line and third-line settings, differentiating it from other studies [55][56] Question: Thoughts on pembro approval in PROC and implications for Rina-S - Management acknowledged the approval as a good option for patients but believes Rina-S can be more transformative for a broader population [61] Question: EPKINLY frontline DLBCL trial expectations - Management emphasized that the primary endpoint is progression-free survival, with expectations for EPKINLY to be transformative in combination with R-CHOP [66][68]